Today: 27 June 2026
Broadcom stock slips after-hours: AVGO price, new 6G BroadPeak chip and VMware partner shake-up in focus
21 February 2026
2 mins read

Broadcom stock slips after-hours: AVGO price, new 6G BroadPeak chip and VMware partner shake-up in focus

New York, Feb 20, 2026, 18:35 EST — Trading after the bell

  • Broadcom shares slipped Friday, showing little movement in after-hours trading.
  • On Thursday, the company rolled out a radio chip built for next-gen wireless gear—ready for 6G.
  • Broadcom is set to scrap VMware’s lowest reseller tier in EMEA this May, according to a report.

Broadcom Inc. slipped 0.4% to finish Friday at $332.65, after swinging between $329.76 and $340.00. After-hours moves were muted. Volume landed around 17.6 million shares, trade data showed.

Even a slight decline was notable here. Broadcom sits right where two big-money themes cross: data-center chips for AI expansion and the VMware software segment, which Broadcom has been refashioning since its 2023 acquisition.

That’s why even subtle headlines carry weight. Investors are scanning for clues that might shift expectations before the next update—watching demand for networking silicon, and hunting for any sign VMware’s channel strategy is finding its footing.

Stocks in the U.S. closed out Friday on a positive note, the S&P 500 gaining 0.7% and the Nasdaq tacking on 0.9%, following a Supreme Court ruling that overturned former President Donald Trump’s sweeping tariff measures, according to the Associated Press. Broadcom, however, lagged behind as the rally picked up late in the session.

Broadcom rolled out its BroadPeak radio digital front-end SoC on Thursday, targeting massive MIMO setups in modern cell towers. The company said the 5-nanometer chip combines DFE and data converters, covers 400 MHz to 8.5 GHz, and slashes power consumption by as much as 40% compared to current massive MIMO and remote radio head solutions. “The BroadPeak SoC integrates DFE and AFE with high-linearity data converters at 8.5 GHz, delivering up to 40% greater efficiency for next-generation base stations,” said Vijay Janapaty, vice president at Broadcom. Samples are already in the hands of early access partners and customers, according to Broadcom. GlobeNewswire

CRN on Friday reported Broadcom plans to scrap the lowest level of VMware’s reseller partner program in Europe, the Middle East and Africa by May 2026, pushing forward changes already seen in other regions. “The Registered tier will go away in May in EMEA,” said Laura Falko, who leads Broadcom-VMware’s global partner program, in comments to CRN. CRN

Chip names diverged this day, with Nvidia adding roughly 1%. Intel dropped 1.1%, and Broadcom edged 0.4% lower, according to MarketWatch data.

But the other side of that coin: wireless infrastructure cycles tend to drag, and actual 6G is still a ways out—even as vendors tout “6G-ready” gear. Software’s not immune either; stricter VMware partner rules risk stirring more resistance from smaller resellers and could make renewals trickier around the edges.

Monday brings another test for Broadcom: traders are eyeing whether the stock manages to track the broader market’s momentum or just lingers in the middle of the semiconductor group, with investors still processing Friday’s policy-driven shift.

AVGO’s next big moment lands on March 4. That’s when Broadcom will deliver its first-quarter fiscal 2026 results after the bell, with management jumping on a conference call later that afternoon.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

27 June 2026
Snowflake Inc (NYSE:SNOW) surged 9.65% to $248.96 on Friday with trading volume five times the weekly average, driven by FTSE Russell’s U.S. index reconstitution, turning a negative week into a 7.2% gain since June 18, as investors await whether the stock can hold above its previous $225.95–$230.41 range when index-driven liquidity fades next week.
GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
GE stock price rises as Morgan Stanley starts GE Aerospace; American Airlines keeps CFM LEAP engines
Previous Story

GE stock price rises as Morgan Stanley starts GE Aerospace; American Airlines keeps CFM LEAP engines

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop